<DOC>
	<DOCNO>NCT02433522</DOCNO>
	<brief_summary>MAINRITSAN study compare Rituximab azathioprine maintenance therapy ANCA-associated vasculitides . In study , Rituximab ( 5 infusion D1 , D15 , M6 , M12 , M18 ) superior azathioprine ( 2 mg/kg/day ) prevent relapse AAV 28 month inclusion ( Guillevin et al . NEJM 2014 ) . Nevertheless , follow-up study MAINRITSAN , 30 % patient experience relapse 38 month last rituximab infusion ( unpublished data ) . Right , randomize control study carry order evaluate best duration maintenance treatment rituximab . The investigator objective evaluate efficacy long term rituximab treatment prevent relapse ANCA-associated vasculitis patient remission first phase rituximab maintenance treatment . The investigator conduct randomize placebo-controlled trial long term rituximab maintenance treatment ( 46 month ) conventional maintenance treatment ( 18 month ) .</brief_summary>
	<brief_title>Comparison Between Long Term Conventional Maintenance Treatment With Rituximab</brief_title>
	<detailed_description />
	<mesh_term>Vasculitis</mesh_term>
	<mesh_term>Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>First , patient must include MAINRITSAN 2 addition meeting criterion inclusion noninclusion . MAINRITSAN 2 inclusion criterion : Granulomatosis Polyangiitis Or microscopic polyangiitis comply Or kidneylimited disease With without detectable ANCA ( antineutrophil cytoplasmic antibody ) time diagnosis relapse , remission . Who achieve remission use treatment combine corticosteroid immunosuppressive agent , include corticosteroid , cyclophosphamide IV oral ( use another immunosuppressant allow , accord current French guideline , well plasma exchange and/or IV immunoglobulin , rituximab ) . Interval 1 month end immunosuppressant treatment randomization time cyclophosphamide methotrexate use , interval 4 6 month rituximab use Age &gt; 18 year without age limit high diagnosis confirm . Informed signed consent form take part study . Patients must meet following criterion : In complete remission ( BVAS 0 ) 28 month MAINRITSAN2 study . Informed patient accept participate MAINRITSAN 2 sign inform consent extension . Randomized day evaluation primary endpoint MAINRITSAN 2 visit M28 ( last visit protocol ) . Eosinophilic granulomatosis polyangiitis ( EGPA ) History severe allergic manifestation anaphylactic manifestation follow humanized murine monoclonal antibody infusion Pregnant breast feed woman . Contraception require woman could pregnant treatment follow year follow last infusion . Infection HIV ( positive serology ) , HCV ( positive serology ) , HBV ( HBsAg positive antiHBc antibody positive antiHBs antibody negative ) Uncontrolled infection time inclusion extend followup study . Other severe bacterial , viral , mycobacterial fungal infection ( ) , occur within last 3 month randomization . A severe infection define hospitalization , life organ threaten . Severe chronic obstructive bronchopathy ( FEV &lt; 50 % dyspnea stage III ) . Cardiac failure , stage IV accord NYHA classification . Recent history coronary artery disease ( &lt; 1 month ) . Ongoing malignancy hematologic disease within 5 year inclusion . Patient severe immunodepression characterize clinical manifestation . Participation another concomitant therapeutic study ( except observational study study without therapeutic intervention ) . Psychiatric disease may interfere study . Non affiliation health insurance . Uncontrolled severe cardiac disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>ANCA-associated vasculitides</keyword>
	<keyword>Maintenance treatment</keyword>
	<keyword>Rituximab</keyword>
	<keyword>Granulomatosis polyangiitis</keyword>
	<keyword>Microscopic polyangiitis</keyword>
</DOC>